Taxonomy, Diversity and Cultivation of the Oudemansielloid/Xeruloid Taxa Hymenopellis, Mucidula, Oudemansiella, and Xerula and with Respect to Their Bioactivities: A Review.
Average rating
Cast your vote
You can rate an item by clicking the amount of stars they wish to award to this item.
When enough users have cast their vote on this item, the average rating will also be shown.
Star rating
Your vote was cast
Thank you for your feedback
Thank you for your feedback
Authors
Niego, Allen GraceRaspé, Olivier
Thongklang, Naritsada
Charoensup, Rawiwan
Lumyong, Saisamorn
Stadler, Marc
Hyde, Kevin D
Issue Date
2021-01-13
Metadata
Show full item recordAbstract
The oudemansielloid/xeruloid taxa Hymenopellis, Mucidula, Oudemansiella, and Xerula are genera of Basidiomycota that constitute an important resource of bioactive compounds. Numerous studies have shown antimicrobial, anti-oxidative, anti-cancer, anti-inflammatory and other bioactivities of their extracts. The bioactive principles can be divided into two major groups: (a) hydrophilic polysaccharides with relatively high molecular weights and (b) low molecular medium polar secondary metabolites, such as the antifungal strobilurins. In this review, we summarize the state of the art on biodiversity, cultivation of the fungi and bioactivities of their secondary metabolites and discuss future applications. Although the strobilurins are well-documented, with commercial applications as agrochemical fungicides, there are also other known compounds from this group that have not yet been well-studied. Polysaccharides, dihydro-citrinone phenol A acid, scalusamides, and acetylenic lactones such as xerulin, also have potential applications in the nutraceutical, pharmaceutical and medicinal market and should be further explored. Further studies are recommended to isolate high quality bioactive compounds and fully understand their modes of action. Given that only few species of oudemansielloid/xeruloid mushrooms have been explored for their production of secondary metabolites, these taxa represent unexplored sources of potentially useful and novel bioactive metabolites.Citation
J Fungi (Basel). 2021 Jan 13;7(1):51. doi: 10.3390/jof7010051.Affiliation
HZI,Helmholtz-Zentrum für Infektionsforschung GmbH, Inhoffenstr. 7,38124 Braunschweig, Germany.Publisher
MDPIPubMed ID
33451109Type
ReviewLanguage
enEISSN
2309-608Xae974a485f413a2113503eed53cd6c53
10.3390/jof7010051
Scopus Count
The following license files are associated with this item:
- Creative Commons
Related articles
- A new species and new records of Hymenopellis and Xerula (Agaricales, Physalacriaceae) from China.
- Authors: Liu YJ, Qi ZX, Li Y, Yue L, Zhao GP, Gui XY, Dong P, Wang Y, Zhang B, Li X
- Issue date: 2023
- Introduction of two novel species of Hymenopellis (Agaricales, Physalacriaceae) from Thailand.
- Authors: Niego AGT, Thongklang N, Hyde KD, Raspé O
- Issue date: 2023
- Submerged cultivation of medicinal mushrooms: bioprocesses and products (review).
- Authors: Elisashvili V
- Issue date: 2012
- Macrofungi as a Nutraceutical Source: Promising Bioactive Compounds and Market Value.
- Authors: Niego AG, Rapior S, Thongklang N, Raspé O, Jaidee W, Lumyong S, Hyde KD
- Issue date: 2021 May 19
- Antibiotics from basidiomycetes. XVIII. Strobilurin C and oudemansin B, two new antifungal metabolites from Xerula species (Agaricales).
- Authors: Anke T, Besl H, Mocek U, Steglich W
- Issue date: 1983 Jun